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Background

The greater New Orleans area emerged as an early epicenter of the COVID-19 pandemic,
with one of the highest infection and death rates per capita in the United States.1 The first
case of COVID-19 in an obstetric patient at Tulane Lakeside Hospital occurred on March 22,
2020. Given increasing concern for asymptomatic carriers, the labor and delivery unit implemented universal testing of all patients and their support partners starting on April 1, 2020.

New Orleans, LA 70112
(cdola@tulane.edu)

Methods

A retrospective chart review of all obstetric encounters was performed to determine the
incidence of COVID-19, characterize the natural history of COVID-19 and evaluate obstetric
and neonatal outcomes.

Results

Over a 5 week period of universal testing, there were 12/254 (4.72%) confirmed cases
of COVID-19; 58% of COVID-positive patients were asymptomatic. The majority of the
symptomatic COVID-19 patients had a mild course of the infection, similar to results from
a previous study.2 As of completion of the study period, only 4 COVID-19-positive patients
delivered; all of them had uncomplicated intra- and postpartum courses. There was no evidence of vertical transmission of COVID-19.

Conclusion

These results confirm the asymptomatic carrier rate is high and support the case for universal testing in high prevalence cities. Ultimately, universal testing allows for a timely identification of disease, initiation of isolation and contact precautions and appropriate allocation
of personal protective equipment (PPE).
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Introduction

The novel coronavirus, severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), initially
began as a cluster of pneumonia cases in Wuhan, China in late 2019.3 It rapidly spread across
China and the globe before the World Health
Organization recognized it is as a pandemic on
March 11, 2020.4,5 There are now more cases in
the United States than any other nation in the
world.6 Since the first documented coronavirus
disease 2019 (COVID-19) case in the state of

Louisiana on March 9, 2020, there have been
116,280 cases as of August 1, 2020. The majority
of Louisiana COVID-19 cases are concentrated
in densely populated areas, including the greater New Orleans community, with more than
24,000 cases in Jefferson and Orleans parishes
alone.7
COVID-19 is caused by a betacoronavirus
named SARS-CoV-2 virus. It is genetically
similar to the coronaviruses that causes se-

www.hcahealthcarejournal.com
© 2020 HCA Physician Services, Inc. d/b/a
Emerald Medical Education

HCA Healthcare
Journal of Medicine

405

HCA Healthcare Journal of Medicine

vere acute respiratory syndrome (SARS)8 and
Middle East respiratory syndrome (MERS).9
The primary means of transmission is by direct
person-to-person contact via respiratory droplets, and infection results in respiratory illness
that can range from asymptomatic to mild,
to critical disease and, in severe cases, death.
Respiratory tract infections in pregnancy have
historically increased the risk of fatal maternal
and neonatal outcomes.8 SARS has been well
known to result in maternal death, miscarriage,
IUGR and preterm delivery.9 MERS was similarly attributed to an increase risk of maternal
death and stillbirth.10 In addition, there were
no cases of vertical transmission with SARS
or MERS.9-11 Although information regarding
pregnancy outcomes is limited, early reports
suggest that SARS-CoV-2 infection may have
a more indolent course compared to SARS,
MERS or the influenza virus.8 According to the
American College of Obstetrics & Gynecology (ACOG), pregnant women with COVID-19,
therefore, do not appear to be at an increased
risk of infection or at risk for severe morbidity.12
Pregnant women with co-morbidities appear
to have similar risk of morbidity as non-pregnant patients with comorbidities.12
On March 22, 2020, Tulane-Lakeside Hospital
identified its first patient with COVID-19 infection. A 32-year-old gravida 8, para 3133 with
type 2 diabetes mellitus at 22 weeks gestational age presented with fever, cough and elevated
blood glucose. She was tested for SARS-CoV-2,
and the patient was transferred to the intensive care unit (ICU) for management of diabetic ketoacidosis. Up until mid-March, our facility
relied on state testing for COVID-19. As results
were not received for 2–3 days, she was treated as a presumptive positive for COVID-19.
SARS-CoV-2 polymerase chain reaction (PCR)
testing returned positive 1 day after she was
discharged home with precautions to self-quarantine.
Following this first case, several patients
testing positive for SARS-CoV-2 were asymptomatic, which was consistent with other early
reports suggesting that SARS-CoV-2 may have
substantial community spread via asymptomatic individuals.13,14 This diagnosis was further
complicated by delayed test results. For example, a woman presented in active labor and delivered before her test resulted as positive after
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delivery. This delayed test result caused exposure, delayed isolation and neonate testing and
also highlights the need for universal testing
with a rapid turnaround time in all patients
presenting in labor. A report from New York
City raised similar concerns about asymptomatic presentations of the SARS-CoV-2 virus in
the obstetric population.15 On April 1, 2020, the
labor unit initiated universal rapid testing of
COVID-19 infection in all patients and support
people presenting to the labor unit for delivery
or triage. We take this opportunity to describe
our early experiences with universal rapid testing of COVID-19 infection in a cohort of obstetrics patients and their support persons.

Materials and Methods
Study Design

A retrospective chart review was performed
after approval was obtained from the institutional review board (IRB). Data was collected on patients tested for COVID-19 at
Tulane-Lakeside Hospital’s labor and delivery
unit from April 1 to May 7, 2020. Tulane Lakeside Hospital is the obstetrics hospital for the
Tulane Obstetrics and Gynecology residency
program but also has admissions from community physicians. The hospital is located in one of
Louisiana’s parishes with the highest COVID-19
prevalence.7
Beginning in mid-March 2020, all patients
presenting to the hospital were screened in the
emergency department for COVID-19 symptoms and risks factors, including fever, cough,
shortness of breath, recent travel and known
sick contacts. Initially, RT-PCR (Roche Cobas
6800) testing was performed only for those
with COVID-19 symptoms or known exposure.
Testing at our hospital was implemented in
stages. (Table 1) During the first stage of testing beginning on April 1, 2020, RT-PCR testing
was completed prior to a scheduled hospital
admission for labor induction or cesarean delivery, regardless of symptoms, to allow results
to be available before their procedure. These
patients were tested via nasopharyngeal swab
using the Roche Cobas 6800 analyzer.
In the second stage of testing, started on April
8, 2020, rapid testing via isothermal nucleic acid
amplification using the Abbott ID NOW test
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Table 1. Hospital protocol for COVID-19 testing.
Protocol
Date
Limited Testing

March 22 - 31, 2020

April 1-7, 2020
Universal Testing
After April 8, 2020

Hospital Criteria for Testing

Patients reporting symptoms of COVID-19,
exposure to sick contacts, or recent travel to high
prevalence areas*
Patients admitted for labor or scheduled for
induction of labor or cesarean delivery
All patients presenting to the labor unit for any
complaint

*SARS-CoV-2 testing was performed on patients having at least one symptom.

was completed on all patients presenting to
the labor and delivery unit for any complaints;
testing was also performed on their support
person if the patient required admission. The
support person who tested positive was not
allowed on the labor unit if the patient tested
negative and the patient could elect another
support person who would also be tested for
COVID-19. In a situation when the patient tested positive, a positive labor support person was
allowed to stay in the room with the patient.

Data Collection

Data collection included maternal demographics, medical and obstetric conditions, results
of COVID-19 and other diagnostic testing and
maternal outcomes. Neonatal data collection
included demographics, APGAR scores, birth
weight, SARS-CoV-2 testing results and postnatal course.
Descriptive and comparison analyses were
performed. Student’s t-test, chi-square test
and Fischer test, when applicable, were performed to evaluate differences between
COVID-19-positive and COVID-19-negative
groups, with a p-value <0.05 considered significant. Analysis was conducted in Microsoft Excel
(Microsoft, Redmond, WA, USA) and using
IBM SPSS Statistics Software package (IBM,
Armonk, NY, USA).

Results

Implementation of a Universal Testing
Protocol

During the first stage of universal testing
(April 1–7, 2020), only patients scheduled for
labor induction, scheduled cesarean section
or admitted for delivery were tested. Howev-

er, following full implementation of universal
testing on April 8, 2020, all patients presenting
to the labor unit for triage or admission for any
reasons were tested. (Table 1)
Results are available on 254 patients; 12 (4.7%)
were COVID-19-positive and 242 (95.3%)
were COVID-19-negative. Among the 12
COVID-19-positive women, 5 (41.7%) were
symptomatic, while 7 (58.3%) were asymptomatic on presentation. Forty-three (16.9%) patients underwent PCR testing using the Roche
Cobas analyzer, and 212 (83.1%) patients were
tested using the Abbott ID NOW rapid platform. The Roche test resulted positive in 5/43
(11.6%) encounters and the Abbott ID in 7/212
(3.3%) encounters.

Patient Characteristics

We described a study population that is diverse
in ethnicity: 20.2% Caucasian, 43.5% African
American and 36.3% Hispanic and other ethnicity. They had a high mean BMI, 30.9 ± 7.0 kg/m2,
with 12.6% meeting the BMI criteria for morbid
obesity; 8.4% had hypertension, 5.7% had either gestational hypertension or preeclampsia,
3.4% had pre-existing diabetes and 6.1% had
gestational diabetes.
The comparison of maternal demographics,
obstetrical characteristics and neonatal outcomes between those who tested positive and
those who tested negative for COVID-19 are
presented in Table 2. No significant difference
was noted between the 2 groups, except that
COVID-19-positive women were significantly
older than COVID-19-negative women (31.7 ±
6.7 vs 27.7 ± 6.0 years, respectively; p = 0.03).
Characteristics of COVID-19-positive patients
are presented in Table 3.
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Table 2. Comparison of COVID-19-positive and -negative patients.
COVID (+)
COVID (-)
(N=12)
(N=242)

P-value

Age

31.7 ± 6.7

27.7 ± 6.9

0.03

Gravidity

2.6 ± 1.8

2.8 ± 1.9

NS

Parity

1.3 ± 1.9

1.3 ± 1.3

NS

Caucasian

1 (8.3%)

52 (21.5%)

NS

African American

4 (33%)

105 (43.4%)

NS

Hispanic or other

7 (58%)

85 (35.1%)

NS

33.1 ± 7.7

30.8 ± 6.9

NS

2 (16.7%)

29 (12%)

NS

0

9 (3.7%)

NS

Gestational diabetes

1 (8.3%)

14 (5.8%)

NS

Chronic hypertension

3 (25%)

19 (7.8%)

0.07

0

15 (6.2%)

NS

Gestational Age at testing

32.0 ± 7.2

32.2 ± 10.0

NS

Gestational Age at delivery

39.6 ± 0.5

37.2 ± 5.7

NS

3249.8 ± 11.3

3094.0 ±884.3

NS

Apgar score @ 1min

8.5 ± 0.6

7.5 ± 2.3

NS

Apgar score @ 5min

9.0 ± 0

8.4 ± 2.0

NS

Race

BMI
Maternal condition
Morbid obesity
Pre-gestational diabetes

Gestational hypertension/Preeclampsia

Neonatal birthweight (grams)

Symptomatic COVID-19-Positive
Patients

Symptomatic COVID-19 patients presented with fever (n=2), cough (n=4), shortness
of breath (n=1) or other symptoms such as
dizziness, syncope and loss of smell or taste
(n=5). Two patients had chest X-rays and only 1
showed signs of reactive lung disease. (Table 3)
The first patient with symptoms of COVID-19
infection was admitted to our Obstetrics ICU
for management of diabetic acidosis and not
for her COVID-19 symptoms. Her COVID-19
test result did not return until after she was
discharged. Other symptomatic patients had
an indolent course as previously characterized
by fever, cough, fatigue, myalgia, gastrointestinal symptoms or anosmia16 and were discharged to home isolation after a brief hospital
408

observation period with supportive care. None
of the patients required ICU admission for critical care of COVID-19 symptoms. All symptomatic COVID-19 patients were still pregnant at
the time of the submission of this report.
During follow-up 14 days after discharge, 4 of
the 5 symptomatic COVID-19 patients reported improved or resolved symptoms. No data is
available at the time of this report on the 1 patient. None had reported worsening COVID-19
symptoms as of the end of the study period.

Asymptomatic COVID-19-Positive
Patients

Of the 7 women who tested positive for
COVID-19 on universal screening and testing
and were asymptomatic for symptoms of
COVID-19, 4 presented to triage to be evaluat-
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Table 3. Characteristics of COVID-19-positive patients.
Patient Symptomatic

EGA

Chief complaint or
reason for admission

Treatment

Delivered?

Neonates
(APGARs;
birthweight)

Discharge/
Outpatient
disposition

1

Yes

22 0/7

Fever, cough,
shortness of breath,
diarrhea, COVID-19positive contact

Acetaminophen

No

Yes*

2

Yes

36 7/7

Loss of taste/smell,
shortness of breath,
COVID-19-positive
contact

-

No

Yes†

3

Yes

26 4/7 Fever, cough,
diarrhea, myalgia

Acetaminophen
Guaifenesin

No

Yes†

4

Yes

20 6/7 Cough, myalgia

-

No

Yes†

5

Yes

28 3/7

Cough, sore throat

-

No

Yes†

6

No

39 4/7

Active labor

-

Yes

8/9; 3324g

No‡

7

No

38 0/7 Active labor

-

Yes

9/9; 3308g

No‡

8

No

28 0/7 Lower back pain

-

No

Yes†

9

No

27 0/7

Contractions

-

No

Yes†

10

No

38 1/7

Contractions

-

Yes

11

No

38 6/7

Abdominal pain

-

No

12

No

39 1/7

Scheduled external
cephalic version

-

Yes

8/9; 3541g

No‡
Yes†

9/9; 2826g

No‡

*Patient was admitted to ICU for management of diabetic acidosis; COVID-19 test result returns after discharge home.
†Patient discharged home following short hospital observation period.
‡Admitted for delivery and postpartum care and not due to COVID-19 symptoms.

ed for abdominal pain or contractions. Labor
was ruled out, and they were discharged home
with precautions to self-quarantine. Two were
admitted for labor and delivery at term. In
addition, 1 patient was admitted for a scheduled external cephalic version and ultimately
delivered by primary low-transverse cesarean
section.
A comparison was made between the symptomatic and the asymptomatic COVID-19
cohorts. Except for a significant difference in
maternal temperature on admission, no difference was noted in other vital signs and laboratory values. (Table 4)
Delivery outcomes: Only 4 asymptomatic
COVID-19-positive women delivered during this
study period—3 vaginal deliveries and 1 primary low transverse cesarean for non-cephalic

presentation. Placental pathology of 1 asymptomatic COVID-19-positive patient was notable for acute chorioamnionitis. However, her
intrapartum and postpartum courses revealed
no evidence of infection.
None of the symptomatic COVID-19-positive
women have delivered yet. With the exception of 1 patient with delayed test results, all
COVID-19-positive patients delivered either
in our dedicated COVID-19 labor and delivery
room or a COVID-19 operating room with proper PPE.
Neonatal outcomes: Neonates from the 4 asymptomatic COVID-19 mothers who delivered
had mean APGAR scores of 8.5± 0.6 and 9.0
+ 0 at 1 and 5 minutes, respectively. (Table 2)
Following COVID-19 diagnosis in the mother,
contact and isolation precautions were im-
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Table 4. Vital signs and laboratory results on presentation of all COVID-19-positive patients.
Symptomatic
Asymptomatic
(N=5)
(N=7)
Vital Signs
P-value
Mean ± SD
Range
Mean ± SD
Range
Temperature

100.2 ± 1.8

99.0-103.1

98.1 ± 0.1

97.9-98.2

0.05

Oxygen saturation

95.0 ± 4.8

87-99

95.5 ± 4.4

90-100

0.88

18.2 ± 1.8

16-20

18.0 ± 1.6

16-20

0.87

101.2 ± 17.0

78-120

78.3 ± 18.3

52-96

0.06

12.2 ± 0.9

11.1-13.0

11.8 ± 0.8

4.2-11.9

0.56

7.5 ± 3.7

4.6-13.1

7.6 ± 3.9

11.0-12.5

0.98

Lymphocyte

1.9 ± 1.3

0.56-3.44

1.7 ± 0.2

1.46-1.81

0.75

Neutrophil

4.9 ± 2.4

3.15-8.39

5.8 ± 4.9

2.35-9.31

0.87

0.00-0.01

0.1033 ± 0.0

0.07-0.18

0.12

Respiratory rate
Heart rate
Initial Laboratory Values
Hemoglobin
White blood cell count, x109/L
Absolute Count, x109/L

Eosinophil 0.0025 ± 0.0
Sodium, mmol/L

138.0 ± 3.4

133-140

Aspartate aminotransferase, U/L

29.5 ± 13.7

21-50

Alanine aminotransferase, U/L

30.0 ± 20.1

18-60

Creatinine

0.65 ± 0.13

0.5-0.8

4.1

4.1

Lactate dehydrogenase, U/L

191.3 ± 7.8

181-199

Procalcitonin, ng/mL

0.11 ± 0.06

0.07-0.18

C-reactive protein, mg/dL

plemented, and the neonates were tested for
SARS-CoV-2. No neonates tested positive for
SARS-CoV-2 at either 24 or 48 hours. Support
partners: To date, no support persons have
tested positive for the virus.

Discussion

Principle Findings

COVID-19 is detected in asymptomatic parturients. Timely identification of these asymptomatic carriers in the setting of obstetrics care is
important for early implementation of isolation
and contact precautions, appropriate allocation
of PPE and proper care of the neonate.

Results in the Context of What Is
Known

Our study confirms previous findings that most
cases of COVID-19, in both non-pregnant and
pregnant populations, present with mild disease. In non-pregnant populations, the Center
for Disease Control and Prevention in China
found that 81% of COVID-19-positive cases had
mild disease, defined as patients with or without mild pneumonia, 14% had severe disease
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with dyspnea, hypoxia, and pneumonia and
5% had critical disease, including respiratory
failure and shock.2 Similar rates of mild respiratory disease, most commonly presenting with
fever and cough, were also found in pregnant
women.2,14,17,18 Following delivery, there were no
cases of severe pneumonia or maternal death
in these patients.17-20
This retrospective chart review study identified
the asymptomatic carrier rate of SARS-CoV-2
infection during a period of universal rapid
testing. We observed reassuring maternal
and fetal outcomes in pregnant women with
COVID-19, both with and without symptoms.
Prior to the universal testing period, our first
COVID-19-positive patient was admitted to
the ICU for the treatment of diabetic ketoacidosis and not for respiratory issues; her
COVID-19-positive result returned after she
was discharged. Following universal testing at
our hospital, no COVID-19-positive patients
required intensive care. Of the symptomatic
COVID-19-positive patients, only 1 had signs of
reactive lung disease on imaging.
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The findings in this New Orleans hospital highlight the prevalence of asymptomatic COVID-19
on our labor unit, consistent with findings
from other regions with a high incidence of
COVID-19.17 Studies from New York City, the initial epicenter of COVID-19 in the US, identified
SARS-CoV-2 infection in 15.3% of patients14 and
asymptomatic infection in 32.6%13 to 87.9%14 of
COVID-19 patients with universal testing.14,20
While our COVID-19-positive rate of 4.7% is
lower, which correlates to a lower infection
rate in New Orleans compared to New York
City,21 our asymptomatic positive rate at 58.3%
is comparable. Although the true number of
asymptomatic cases is unknown, our studies
highlight the importance of universal testing
to identify asymptomatic carriers, especially in
areas with higher rates of COVID-19.
We recognize the possibility that asymptomatic pregnant women could present at the beginning of their illness and, therefore, had not yet
developed severe COVID-19 symptoms. Breslin
et al. found that most asymptomatic women
developed fever and symptoms throughout
their hospitalization.13 Wang et al. described
a symptomatic patient who initially tested
negative for COVID-19, and subsequent repeat
COVID-19 testing and a CT scan confirmed she
was COVID-19-positive.22 However, in our study,
all 4 COVID-19-positive patients who delivered
remained asymptomatic and afebrile throughout hospitalization without the most common
symptoms of fever and cough. Additionally, the
majority of symptomatic COVID-19-positive
patients improved or had resolution of symptoms 14 days after presentation. Although reassuring, these studies do not provide a comprehensive overview of the potential dangers of
COVID-19. Despite recent reassuring findings
about the absence of significant maternal or
fetal risk, caution should still be advised.

Clinical Implications

Although this report and prior studies suggest reassuring outcomes for COVID-19-positive pregnant patients and their neonates,
COVID-19 remains a major public health threat.
Early COVID-19 diagnosis allows for timely identification of infectious patients, quick
establishment of isolation and contact precautions and preservation of PPE resources.
Universal testing also helps in informing neonatal testing, isolation from other infants and rec-

ommended separation or contact precautions
from the mother during the infectious period.
These findings underscore the importance of
universal testing and should encourage other
facilities to pursue similar testing procedures.
ACOG currently endorses universal testing in
areas of wide community spread and where
the number of asymptomatic presentations is
likely high.12 While this is appropriate for cities
such as New Orleans, other cities may not have
such a high prevalence of disease. Furthermore,
if testing is not universally available, testing
should be prioritized for symptomatic patients
or those with a high suspicion of disease and/or
comorbidities.

Research Implications

Many unanswered questions remain about
COVID-19 and its effect on the peripartum
period. Given the novel nature of this virus,
the timing of maternal infection and the
importance of fetal gestational age remains
unknown. Future research on the effects of
COVID-19 infection in first or second trimester
gestation on neonatal outcomes is warranted.

Strengths and Limitations

Strengths: While most case series only evaluate COVID-19-positive patients, this study
considered all women who were tested and
evaluated the characteristics of COVID-19-negative patients. This COVID-19-negative control
group served as a baseline to identify differences in maternal and neonatal outcomes. High
rates of COVID-19 infection in the greater New
Orleans area, combined with wider accessibility
to testing, permitted ongoing surveillance of
the obstetrics population. In addition, no other
facility to our knowledge has initiated testing
of support persons or developed an algorithm
embedded into the intake process to safely
address the support person testing positive.
Although no support partners tested positive,
an important example was set for all other
labor units to test support people for COVID-19
universally. This also raises the question on the
transmission of COVID-19 infection. Assuming
the majority of the labor support persons for
our patients have close contact with the patients, they somehow tested negative. Further
research in the transmission of the disease
is indicated. Can the negative test results be
explained by the fact that the viral load in these
411
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asymptomatic women is low, and therefore,
the infectious nature of the disease is low?
Limitations: While the Abbott ID NOW test
provides the fastest results—in 13 minutes or
less—recent reports suggest that ID NOW
might be the most inaccurate test.23 Multiple
reports of false negative results, including a
false negative rate of 33.3–50%,24 suggest that
the 4.7% COVID-19 infection rate reported in
our study is perhaps underreported.
A small sample size is another limitation of our
study, resulting in a type II error where abnormal laboratory findings and more critically ill
pregnant patients were not seen in our study
sample.

Conclusion

A strategy of rapid universal testing of all
patients and their support partner has obvious benefits. Universal testing identified many
asymptomatic pregnant patients. Additionally,
testing of support persons allowed loved ones
to participate in the delivery process in a safe
way that limits spread of the virus to health
care workers and the community at large.
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